/LUCD
LUCD Stock - Lucid Diagnostics Inc.
Healthcare|Medical - DevicesNASDAQ
$1.12-0.88%
$0.01 (-0.88%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+78.6%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LUCD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.11 – $1.13
TARGET (TP)$2.00
STOP LOSS$1.03
RISK/REWARD1:9.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$1.80
52W Low$0.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.35M | $2.43M | $377,000 | $500,000 | N/A |
| Gross Profit | $-3,920,000 | $-6,050,000 | $-3,237,000 | $-85,000 | N/A |
| Gross Margin | -90.2% | -249.2% | -858.6% | -17.0% | N/A |
| Operating Income | $-46,052,000 | $-48,482,000 | $-56,171,000 | $-27,419,000 | $-8,280,000 |
| Net Income | $-45,529,000 | $-52,666,000 | $-56,171,000 | $-28,078,000 | $-8,280,000 |
| Net Margin | -1047.6% | -2169.1% | -14899.5% | -5615.6% | N/A |
| EPS | $-1.05 | $-1.26 | $-1.55 | $-0.78 | $-0.22 |
Company Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LUCDBeat Rate
53%
Last 17 quarters
Avg Surprise
-18.1%
EPS vs Estimate
Beats / Misses
9/8
Last 12 quarters
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
+11.5%
$-0.23vs$-0.26
Q2 24
+22.2%
$-0.21vs$-0.27
Q3 24
+9.1%
$-0.20vs$-0.22
Q4 24
-25.0%
$-0.20vs$-0.16
Q1 25
-26.7%
$-0.19vs$-0.15
Q2 25
-77.8%
$-0.16vs$-0.09
Q3 25
-11.1%
$-0.10vs$-0.09
Q4 25
-66.7%
$-0.10vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.09 | $-0.16 | -77.8% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-0.15 | $-0.19 | -26.7% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.27 | $-0.21 | +22.2% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.35 | $-0.24 | +31.4% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $0.38 | $-0.29 | -176.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.40 | $-0.28 | +30.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.36 | $-0.28 | +22.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.30 | $-0.23 | +23.3% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.20 | $-0.32 | -60.0% | ✗ MISS |
Q4 2021 | Nov 23, 2021 | $-0.32 | $-0.49 | -53.1% | ✗ MISS |
Q4 2021 | Oct 14, 2021 | — | $-0.17 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.10 | — | — |
Latest News
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8.25
📈 PositiveBenzinga•Dec 10, 2025, 10:29 AM
Lucid Diagnostics shares are trading higher after the company reported real-world data showing a 95% technical success rate for EsoGuard procedures, most completed in under two minutes with no serious adverse events.
📈 PositiveBenzinga•Dec 9, 2025, 01:13 PM
Lucid Diagnostics Announces Data From Real-World Experience Of Esophageal Precancer Detection With EsoGuard, Showing 95% Technical Success Rate with 95% Of Procedures Completed In Under Two Minutes With no Serious Adverse Events
📈 PositiveBenzinga•Dec 9, 2025, 01:09 PM
Lucid Diagnostics Files Prospectus To Raise Up To $175M Through Sale Of Stock, Debt And Warrants
➖ NeutralBenzinga•Dec 5, 2025, 10:09 PM
Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 11:00 AM
Lucid Diagnostics Q3 Adj. EPS $(0.10) Beats $(0.11) Estimate, Sales $1.211M Miss $1.357M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 01:09 PM
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8
📈 PositiveBenzinga•Oct 6, 2025, 10:06 AM
Lucid Diagnostics shares are trading lower after the company announced the pricing of its $25 million public offering of 25 million shares at $1.00 per share.
📉 NegativeBenzinga•Sep 10, 2025, 04:59 PM
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 04:34 PM
Lucid Diagnostics dips after pricing $25M stock offering
📉 NegativeSeeking Alpha•Sep 10, 2025, 12:29 PM
Lucid Diagnostics Announces $25M Public Offering Of 25M Shares Of Common Stock At A Price Of $1.00/Share
📉 NegativeBenzinga•Sep 10, 2025, 12:07 PM
Lucid Diagnostics announces proposed public offering of common stock
➖ NeutralSeeking Alpha•Sep 9, 2025, 08:10 PM
Lucid Diagnostics shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Sep 9, 2025, 08:03 PM
Lucid Diagnostics Reveals Proposed Public Offering of Common Stock; Size Not Disclosed
➖ NeutralBenzinga•Sep 9, 2025, 08:02 PM
BTIG Maintains Buy on Lucid Diagnostics, Raises Price Target to $2.5
📈 PositiveBenzinga•Sep 5, 2025, 10:32 AM
Frequently Asked Questions about LUCD
What is LUCD's current stock price?
Lucid Diagnostics Inc. (LUCD) is currently trading at $1.12 per share. The stock has moved -0.88% today.
What is the analyst price target for LUCD?
The average analyst price target for LUCD is $2.00, based on 1 analyst.
What sector is Lucid Diagnostics Inc. in?
Lucid Diagnostics Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is LUCD's market cap?
Lucid Diagnostics Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does LUCD pay dividends?
No, Lucid Diagnostics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPYX
Apyx Medical Corporation
$3.49
Mkt Cap: $0.1B
AVR
Anteris Technologies Global Corp.
$4.94
Mkt Cap: $0.2B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
IXHL
Incannex Healthcare Limited
$0.44
Mkt Cap: $0.0B
OWLT
Owlet, Inc.
$14.05
Mkt Cap: $0.2B
RCEL
AVITA Medical, Inc.
$3.46
Mkt Cap: $0.1B
RPID
Rapid Micro Biosystems, Inc.
$3.15
Mkt Cap: $0.1B
SCLX
Scilex Holding Company
$14.35
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
STSS
Sharps Technology, Inc.
$2.22
Mkt Cap: $0.1B
Explore stocks similar to LUCD for comparison